A retrospective study of predictive factors for unexpectedly prolonged or shortened progression-free survival and overall survival among patients with metastatic renal cell carcinoma who received first-line targeted therapy

被引：0
|
作者：
Sung Han Kim
Sohee Kim
Jungnam Joo
Ho Kyung Seo
Jae Young Joung
Kang Hyun Lee
Jinsoo Chung
机构：
[1] Hospital of National Cancer Center National Cancer Center,Department of Urology, Center for Prostate Cancer
[2] Hospital of National Cancer Center National Cancer Center,Biometric Research Branch, Clinical Research Coordination Center
[3] Center for Prostate Cancer,undefined
[4] National Cancer Center,undefined
来源：
BMC Cancer | / 16卷
关键词：
Renal cell carcinoma; Neoplasm metastasis; Prognosis; Overall survival; Progression free survival; Molecular targeted therapy;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] A retrospective study of predictive factors for unexpectedly prolonged or shortened progression-free survival and overall survival among patients with metastatic renal cell carcinoma who received first-line targeted therapy
    Kim, Sung Han
    Kim, Sohee
    Joo, Jungnam
    Seo, Ho Kyung
    Joung, Jae Young
    Lee, Kang Hyun
    Chung, Jinsoo
    [J]. BMC CANCER, 2016, 16
  • [2] Prognostic factors for progression-free and overall survival with sunitinib targeted therapy and with cytokine as first-line therapy in patients with metastatic renal cell carcinoma
    Patil, S.
    Figlin, R. A.
    Hutson, T. E.
    Michaelson, M. D.
    Negrier, S.
    Kim, S. T.
    Huang, X.
    Motzer, R. J.
    [J]. ANNALS OF ONCOLOGY, 2011, 22 (02) : 295 - 300
  • [3] Progression-free survival (PFS) of first-line VEGF-targeted therapy as a prognostic parameter for overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC).
    Seidel, C.
    Fenner, M.
    Reuter, C. W.
    Ganser, A.
    Gruenwald, V.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [4] Progression-Free Survival as a Predictor of Overall Survival in Metastatic Renal Cell Carcinoma Treated With Contemporary Targeted Therapy
    Heng, Daniel Y. C.
    Xie, Wanling
    Bjarnason, Georg A.
    Vaishampayan, Ulka
    Tan, Min-Han
    Knox, Jennifer
    Donskov, Frede
    Wood, Lori
    Kollmannsberger, Christian
    Rini, Brian I.
    Choueiri, Toni K.
    [J]. CANCER, 2011, 117 (12) : 2637 - 2642
  • [5] Bevacizumab as first-line therapy in metastatic renal cell carcinoma. Progression-free survival for 3 years
    Pichler, R.
    Horninger, W.
    Aigner, F.
    Heidegger, I.
    [J]. UROLOGE, 2016, 55 (03): : 381 - 385
  • [6] Progression-Free Survival as a Surrogate Endpoint of Overall Survival in Patients With Metastatic Renal Cell Carcinoma
    Halabi, Susan
    Rini, Brian
    Escudier, Bernard
    Stadler, Walter M.
    Small, Eric J.
    [J]. CANCER, 2014, 120 (01) : 52 - 60
  • [7] Prognostic factors for overall survival with sunitinib as first-line therapy in patients with metastatic renal cell carcinoma (mRCC)
    Patil, S.
    Figlin, R. A.
    Hutson, T. E.
    Michaelson, M. D.
    Negrier, S.
    Kim, S. T.
    Huang, X.
    Motzer, R. J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [8] Assessment of Progression-free Survival as a Surrogate Endpoint for Overall Survival in Patients With Metastatic Renal Cell Carcinoma
    Negrier, S.
    Bushmakin, A. G.
    Cappelleri, J. C.
    Charbonneau, C.
    Sandin, R.
    Michaelson, M. D.
    Figlin, R. A.
    Motzer, R. J.
    [J]. EUROPEAN JOURNAL OF CANCER, 2011, 47 : S163 - S163
  • [9] Progression-free Survival After Second Line of Therapy for Metastatic Clear Cell Renal Cell Carcinoma in Patients Treated with First-line Immunotherapy Combinations
    Fitzgerald, Kelly N.
    Duzgol, Cihan
    Knezevic, Andrea
    Shapnik, Natalie
    Kotecha, Ritesh
    Aggen, David H.
    Carlo, Maria I.
    Shah, Neil J.
    Voss, Martin H.
    Feldman, Darren R.
    Motzer, Robert J.
    Lee, Chung -Han
    [J]. EUROPEAN UROLOGY, 2023, 83 (03) : 195 - 199
  • [10] The magnitude of best tumor shrinkage during second-line targeted therapy affects progression-free survival but not overall survival in patients with metastatic renal cell carcinoma
    Ishihara, Hiroki
    Kondo, Tsunenori
    Omae, Kenji
    Takagi, Toshio
    Izuka, Jumpei
    Kobayashi, Hirohito
    Tanabe, Kazunari
    [J]. JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2016, 46 (06) : 568 - 574
12345